<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791631</url>
  </required_header>
  <id_info>
    <org_study_id>GN18OP439</org_study_id>
    <nct_id>NCT04791631</nct_id>
  </id_info>
  <brief_title>'Distortion as a Predictor of ERM Surgery Outcome'</brief_title>
  <official_title>Does Pre-operative D-chart Score Predict Improvement in VFQ-25 Score Following Surgery for Epiretinal Membrane?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal College of Surgeons of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epiretinal membranes (ERM) consist of an abnormal growth of tissue across the retina and are&#xD;
      present about 6% of people aged 50 and over. They can cause symptoms of distortion (straight&#xD;
      lines appearing bent) or blurred vision. Management options include observation if&#xD;
      asymptomatic, or surgery to peel the membrane if symptomatic. Limited data exists regarding&#xD;
      how to identify patients who are most likely to benefit from surgery.&#xD;
&#xD;
      We propose to measure the effects on distortion (using D chart), visual acuity and&#xD;
      vision-related quality of life (using a validated vision-related quality of life&#xD;
      questionnaire) of ERM surgery. This will allow us to investigate whether pre-operative D&#xD;
      chart score can predict subsequent improvement in quality of life following surgery. We hope&#xD;
      the results will help patients and VR surgeons decide whether or not to proceed with ERM&#xD;
      surgery.&#xD;
&#xD;
      The study will be a prospective case series consisting of patients with symptomatic&#xD;
      epiretinal membranes who choose to have epiretinal membrane surgery. The study participants&#xD;
      will get standard care with the additional administration of a quality of life questionnaire&#xD;
      and measurement of distortion (using a D-chart) at 3 different time points (pre-op, and&#xD;
      post-op at 26 and 52 weeks). Recruitment will be in Glasgow, with a possibility of other&#xD;
      sites being added on at a later stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epiretinal membranes consist of a proliferation of fibrocellular tissue along the inner&#xD;
      aspect of the retina. Over time, this membrane can result in anterior-posterior traction and&#xD;
      cause disruption of the retinal architecture, which can lead to symptoms of blurred vision,&#xD;
      or distorted vision (with straight lines appearing bent or wavy).&#xD;
&#xD;
      Patients with ERM now constitute one of the most common referrals to the vitreoretinal&#xD;
      service. Management of epiretinal membrane includes observation or surgery for severely&#xD;
      symptomatic membranes. The surgery consists of vitrectomy and epiretinal +/- inner limiting&#xD;
      membrane peel. Currently there is limited evidence to help identify which patients with an&#xD;
      epiretinal membrane are the most likely to benefit from this operation, which makes it more&#xD;
      difficult for patients to be able to weigh up the benefits and risks of proceeding with this&#xD;
      elective procedure.&#xD;
&#xD;
      Our study will measure the effects on distortion (using D chart), visual acuity and quality&#xD;
      of life of ERM surgery. Hence it will allow us to investigate whether the pre-op D chart&#xD;
      score can predict subsequent improvement in quality of life following surgery. This will&#xD;
      provide vitreoretinal surgeons and patients with an evidence base regarding the success of&#xD;
      this elective procedure and offer realistic expectations regarding surgical outcomes.&#xD;
      Ultimately, we hope that the results of this study will facilitate the decision of whether or&#xD;
      not to proceed with ERM surgery.&#xD;
&#xD;
      We plan to recruit patients with an epiretinal membrane who choose to undergo surgery at the&#xD;
      time of their clinic appointment within the vitreoretinal service. In addition to standard&#xD;
      care, the study participants will undergo measurements of distortion (using a D-chart,&#xD;
      duration 5-10 minutes) and fill in a quality of life questionnaire. These measurements will&#xD;
      be taken before the operation and at six and twelve months following the operation.&#xD;
&#xD;
      The aims of the study are:&#xD;
&#xD;
        -  To investigate the sustained effect of epiretinal membrane surgery on distortion (using&#xD;
           D-chart), visual acuity and vision-related quality of life (using NEI VFQ-25&#xD;
           questionnaire)&#xD;
&#xD;
        -  To determine the relationship between pre-operative distortion score and post-operative&#xD;
           vision-related quality of life score following ERM surgery&#xD;
&#xD;
      Our study will have a larger number of participants with a longer period of follow up (52&#xD;
      weeks) than comparable studies. It will be the first epiretinal membrane study that measures&#xD;
      distortion using the D-chart, which we believe to be superior to existing tests (such as the&#xD;
      M-chart) which have been used in similar studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VFQ-25 score at final visit (52 weeks after ERM surgery)</measure>
    <time_frame>1 year</time_frame>
    <description>Measure of vision-related quality of life using NEI VFQ-25 quality of life questionnaire, 1 year after surgery for epiretinal membrane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distortion score pre-operatively and at 26 and 52 weeks after ERM surgery</measure>
    <time_frame>1 year</time_frame>
    <description>Distortion score calculated using D-chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity pre-operatively and at 26 and 52 weeks after ERM surgery</measure>
    <time_frame>1 year</time_frame>
    <description>Visual acuity measured in ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related quality of life pre-operatively and at 26 and 52 weeks after ERM surgery</measure>
    <time_frame>1 year</time_frame>
    <description>Vision-related quality of life assessed using NEI VFQ-25 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness pre-operatively and at 26 and 52 weeks after ERM surgery</measure>
    <time_frame>1 year</time_frame>
    <description>Central retinal thickness obtained from OCT scans done in clinic</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Distortion</condition>
  <condition>Quality of Life</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epiretinal membrane surgery</intervention_name>
    <description>Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with epiretinal membranes attending the vitreoretinal clinic at the Tennent&#xD;
        Institute of Ophthalmology in Glasgow, UK, and meeting the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Idiopathic epiretinal membrane&#xD;
&#xD;
          2. Patients undergoing vitrectomy and gas surgery, under local or general anaesthetic&#xD;
&#xD;
          3. Able to give informed consent&#xD;
&#xD;
          4. 18 years old and over&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Epiretinal membrane secondary to retinal detachment, uveitis or retinal vascular&#xD;
             disease&#xD;
&#xD;
          2. Previous vitreoretinal surgery&#xD;
&#xD;
          3. Pre-existing ophthalmic condition which limits the patient's visual acuity (Documented&#xD;
             BCVA 6/36 or worse)&#xD;
&#xD;
          4. Pre-existing ophthalmic conditions which cause metamorphopsia (exudative ARMD, central&#xD;
             serous retinopathy)&#xD;
&#xD;
          5. VA &lt; 6/60&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lona Jawaheer, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Yorston, MBChb</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Greater Glasgow and Clyde</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma McDonough</last_name>
    <phone>+44141 314 4000</phone>
    <email>Emma.McDonough@ggc.scot.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lona Jawaheer</last_name>
    <phone>+447783520779</phone>
    <email>lonajawaheer@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde Clinical Research and Development Central Office</name>
      <address>
        <city>Paisley</city>
        <zip>PA2 7DE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Emma McDonough</last_name>
      <email>Emma.McDonough@ggc.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lona Jawaheer, MBChB</last_name>
      <email>lonajawaheer@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>David Yorston, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lona Jawaheer, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard McGowan, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dawson SR, Shunmugam M, Williamson TH. Visual acuity outcomes following surgery for idiopathic epiretinal membrane: an analysis of data from 2001 to 2011. Eye (Lond). 2014 Feb;28(2):219-24. doi: 10.1038/eye.2013.253. Epub 2013 Dec 6.</citation>
    <PMID>24310238</PMID>
  </reference>
  <reference>
    <citation>Wong JG, Sachdev N, Beaumont PE, Chang AA. Visual outcomes following vitrectomy and peeling of epiretinal membrane. Clin Exp Ophthalmol. 2005 Aug;33(4):373-8.</citation>
    <PMID>16033349</PMID>
  </reference>
  <reference>
    <citation>Pournaras CJ, Emarah A, Petropoulos IK. Idiopathic macular epiretinal membrane surgery and ILM peeling: anatomical and functional outcomes. Semin Ophthalmol. 2011 Mar;26(2):42-6. doi: 10.3109/08820538.2010.544237. Review.</citation>
    <PMID>21469962</PMID>
  </reference>
  <reference>
    <citation>Rahman R, Stephenson J. Early surgery for epiretinal membrane preserves more vision for patients. Eye (Lond). 2014 Apr;28(4):410-4. doi: 10.1038/eye.2013.305. Epub 2014 Jan 10.</citation>
    <PMID>24406414</PMID>
  </reference>
  <reference>
    <citation>Ghazi-Nouri SM, Tranos PG, Rubin GS, Adams ZC, Charteris DG. Visual function and quality of life following vitrectomy and epiretinal membrane peel surgery. Br J Ophthalmol. 2006 May;90(5):559-62. Epub 2006 Jan 18.</citation>
    <PMID>16421185</PMID>
  </reference>
  <reference>
    <citation>Ichikawa Y, Imamura Y, Ishida M. Associations of aniseikonia with metamorphopsia and retinal displacements after epiretinal membrane surgery. Eye (Lond). 2018 Feb;32(2):400-405. doi: 10.1038/eye.2017.201. Epub 2017 Sep 22.</citation>
    <PMID>28937146</PMID>
  </reference>
  <reference>
    <citation>Kinoshita T, Imaizumi H, Miyamoto H, Okushiba U, Hayashi Y, Katome T, Mitamura Y. Changes in metamorphopsia in daily life after successful epiretinal membrane surgery and correlation with M-CHARTS score. Clin Ophthalmol. 2015 Feb 4;9:225-33. doi: 10.2147/OPTH.S76847. eCollection 2015.</citation>
    <PMID>25678770</PMID>
  </reference>
  <reference>
    <citation>Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life. Am J Ophthalmol. 2009 May;147(5):869-74, 874.e1. doi: 10.1016/j.ajo.2008.11.018. Epub 2009 Feb 6.</citation>
    <PMID>19200531</PMID>
  </reference>
  <reference>
    <citation>McGowan G, Yorston D, Strang NC, Manahilov V. D-CHART: A Novel Method of Measuring Metamorphopsia in Epiretinal Membrane and Macular Hole. Retina. 2016 Apr;36(4):703-8. doi: 10.1097/IAE.0000000000000778.</citation>
    <PMID>26441261</PMID>
  </reference>
  <reference>
    <citation>Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001 May;119(5):733-40.</citation>
    <PMID>11346401</PMID>
  </reference>
  <reference>
    <citation>Nichols KK, Mitchell GL, Zadnik K. Performance and repeatability of the NEI-VFQ-25 in patients with dry eye. Cornea. 2002 Aug;21(6):578-83.</citation>
    <PMID>12131034</PMID>
  </reference>
  <reference>
    <citation>Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3354-9. doi: 10.1167/iovs.10-5645.</citation>
    <PMID>21282568</PMID>
  </reference>
  <reference>
    <citation>Owen CG, Rudnicka AR, Smeeth L, Evans JR, Wormald RP, Fletcher AE. Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol. 2006 Jun 9;6:24.</citation>
    <PMID>16764714</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04791631/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04791631/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

